The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
ApexOnco Front Page
Recent articles
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
An anti-ER “Riptac” enters phase 1.
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
BeOne's degrader BG-60366 appears to have been discontinued.
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
